Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by GunnerGon Oct 15, 2020 4:59pm
103 Views
Post# 31723121

RE:RE:Wowser !

RE:RE:Wowser !LMNL already has a $75M fully used LOC they need to pay it back Apr 2024.

The $75M is the only LOC they have announced since restucturing, not sure what you are referring to when you say "simply reinstate the original..."


sah1 wrote: At current burn rate, money runs out in December and that is what is perplexing markets and driving sp lower. TV will not do another major restructure that I am confident of. but another rights offer could be done to raise $50M or so or TV could simply reinstate the original LoCwhich I think was $77M. The latter could be paid back after monetisation of the voucher if one is received or after an equity raise on Nasdaq after Ryplazim approval. The equity raise should be at a minimum of $25 and for at least $150M or so.

All the company has to do is clarify how it intends to fund the runway to Ryplazim approval and early stages of commercialisation and then the sp bleeding should stop.


<< Previous
Bullboard Posts
Next >>